Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials

Table 1 Subgroup analyses of antiplatelet and anticoagulant treatments for the stroke outcomes

Variable	No. of studies	Estimates and 95% CI	P value	I² (%)	P value for within-group heterogeneity	P value for between-group heterogeneity^a
All stroke	39	0.86 (0.80, 0.94)	0.001	25.1	0.083	0.030
OAC	7	0.73 (0.58, 0.92)	0.006	59.1	0.023
Antiplatelet	32	0.90 (0.83, 0.97)	0.004	0.0	0.571
Long-term versus short-term DAPT	24	0.86 (0.78, 0.95)	0.002	0.0	0.672
Novel P₂Y₁₂ inhibitor	4	1.03 (0.87, 1.22)	0.701	0.0	0.584
Others^b	4	0.88 (0.71, 1.08)	0.219	25.3	0.260
Ischemic stroke	21	0.80 (0.71, 0.91)	0.001	48.8	0.007	0.298
OAC	7	0.73 (0.53, 1.01)	0.059	72.6	0.001
Antiplatelet	14	0.83 (0.76, 0.92)	< 0.001	4.1	0.406
Long-term versus short-term DAPT	10	0.84 (0.75, 0.94)	0.002	0.0	0.479
Novel P₂Y₁₂ inhibitor	2	1.00 (0.77, 1.30)	0.981	0.0	0.432
Others^b	2	0.72 (0.58, 0.90)	0.003	0.0	0.388
Hemorrhagic stroke	12	1.36 (1.00, 1.86)	0.051	6.9	0.378	0.782
OAC	3	1.51 (0.80, 2.88)	0.204	2.0	0.360
Antiplatelet	9	1.32 (0.90, 1.94)	0.160	17.2	0.290
Long-term versus short-term DAPT	7	0.96 (0.62, 1.49)	0.858	0.0	0.709
Novel P₂Y₁₂ inhibitor	1	1.76 (0.89, 3.47)	0.103	NA	NA
Others^b	1	2.75 (1.22, 6.17)	0.014	NA	NA
Intracranial hemorrhage	19	1.46 (1.17, 1.81)	0.001	37.7	0.050	0.465
OAC	5	2.01 (1.00, 4.02)	0.049	63.4	0.027
Antiplatelet	14	1.39 (1.12, 1.74)	0.003	27.8	0.157
Long-term versus short-term DAPT	7	1.37 (1.08, 1.75)	0.011	0.0	0.654
Novel P₂Y₁₂ inhibitor	4	1.15 (0.78, 1.71)	0.475	18.4	0.298
Others^b	3	1.64 (0.77, 3.47)	0.197	73.4	0.023

All estimates and P values were analyzed using the random effects model
OAC oral anticoagulant
^aP value for between-group heterogeneity refers to the heterogeneity between OAC and Antiplatelet groups
^bOthers subgroup including 1 study for Orbofiban, 1 study for Cilostazol, 2 study for Vorapaxar

ISSN: 1471-2261